Document text
Principal Investigator: Ralph S Baric
Organization: WASHINGTON UNIVERSITY
Fiscal Year: 2022
Award: $1,202,440
Funding agency: National Institute of Allergy and Infectious Diseases
Project Summary
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a positive-sense single-stranded RNA virus
that was first isolated in Wuhan China in December, 2019. SARS-CoV-2 is the cause of coronavirus disease
2019 (COVID-19), which is now a pandemic and has caused more than 1.3 million confirmed cases and 72,000
deaths, with an estimated case fatality rate of 4%, with substantially higher death rates (~15%) in the elderly or
immunocompromised. Virtually all countries and territories have reported cases, with major epidemics in China,
Italy, Spain, France, Germany, Iran, and the United States. SARS-CoV-2 is thought to be of zoonotic origin, most
likely bats, and is about 75% identical to the original SARS-CoV. Most cases are spread by direct human-to-
human transmission, with community transmission in asymptomatic individuals described. Currently, no
countermeasures are licensed for human use. The development, characterization, and ultimately deployment of
an antibody-based treatment against SARS-CoV-2 could prevent substantial morbidity and mortality, and
possibly mitigate its epidemic spread. This interactive multi-PI proposal leverages complementary expertise in
the Diamond, Crowe, and Baric laboratories to rapidly develop highly neutralizing and therapeutic human
monoclonal antibodies (mAbs) against SARS-CoV-2 for immediate use in humans. To achieve this goal, we will
generate and interrogate human mAbs against SARS-CoV-2 that are obtained from multiple convalescent
subjects. We will identify potently neutralizing mAbs and optimize them for affinity by selecting naturally occurring
somatic variants identified by repertoire sequencing and sibling analysis and Fc effector functions. Protective
activity of top candidate coronavirus mAbs will be tested in newly-generated and optimized mouse models of
SARS-CoV-2 infection, including those expressing human ACE2 receptors (hACE2). To define correlates of
protection, we will use chimeric viruses, shotgun mutagenesis, and neutralization escape to identify the epitopes
of our most protective mAbs. Our team has extensive experience in the generation, characterization and
optimization of antibodies, CoV biology, and animal models of disease and protection. A therapy composed of
one to three highly neutralizing mAbs may provide an immediate countermeasure against the pandemic spread
of SARS-CoV-2 and help establish correlates of structural and functional humoral protection that ultimately
inform vaccine efforts.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><ACE2><Affinity><Alanine><Animal Disease Models><Antibodies><Antibody Therapy><Antigenic Determinants><Antigens><Assay><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><Bats><Binding><Binding Determinants><Bioassay><Biologic Assays><Biological Assay><Biology><Blood Serum><Body Tissues><COVID crisis><COVID epidemic><COVID pandemic><COVID-19><COVID-19 crisis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 virus><COVID19><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 pandemic><COVID19 public health crisis><COVID19 virus><CV-19><CV19><Case Fatality Rates><Case Study><Cell Isolation><Cell Segregation><Cell Separation><Cell Separation Technology><Cessation of life><Charge><China><Chiroptera><Clinical Treatment Moab><Clone Cells><CoV emergence><CoV-2><CoV2><Combined Modality Therapy><Containment><Coronaviridae><Coronavirus><Country><Data><Death><Death Rate><Deuterium><Development><Diamond><Disease><Disease model><Disorder><Elderly><Engineering><Epidemic><Epitopes><Evaluation><Fever><France><Generations><Genetics-Mutagenesis><Germany><Glycoproteins><Goals><H element><H2 isotope><HCoV><Half-Life><Hu-mABs><Human><Hydrogen><Immunocompromised><Immunocompromised Host><Immunocompromised Patient><Immunosuppressed Host><Individual><Infection><Interferometry><Intervention><Intervention Strategies><Iran><Italy><Laboratories><Location><Lung><Lung Respiratory System><MERS corona virus><MERS coronavirus><MERS virus><MERS-CoV><Mainland China><Mass Photometry/Spectrum Analysis><Mass Spectrometry><Mass Spectroscopy><Mass Spectrum><Mass Spectrum Analyses><Mass Spectrum Analysis><Mediating><Mice><Mice Mammals><Middle East Respiratory Syndrome Corona Virus><Middle East Respiratory Syndrome Coronavirus><Middle East Respiratory Syndrome Virus><Middle East Respiratory Syndrome-CoV><Middle Eastern Respiratory Syndrome Corona virus><Middle Eastern Respiratory Syndrome Coronavirus><Middle Eastern Respiratory Syndrome Virus><Middle Eastern Respiratory Syndrome-CoV><Modern Man><Molecular Interaction><Monitor><Monoclonal Antibodies><Morbidity><Morbidity - disease rate><Multimodal Therapy><Multimodal Treatment><Murine><Mus><Mutagenesis><Mutagenesis Molecular Biology><Pathogenesis><Pathogenicity><Pneumonia><Prevention><Prophylactic treatment><Prophylaxis><Proteins><Pyrexia><RNA Viruses><Receptor Protein><SARS><SARS Virus><SARS corona virus><SARS corona virus 2><SARS coronavirus><SARS coronavirus disease><SARS-Associated Coronavirus><SARS-CO-V2><SARS-COVID-2><SARS-CoV><SARS-CoV disease><SARS-CoV-1><SARS-CoV-2><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 pandemic><SARS-CoV2><SARS-CoV2 epidemic><SARS-CoV2 pandemic><SARS-Related Coronavirus><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Scanning><Serum><Severe Acute Respiratory Coronavirus><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV disease><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe Acute Respiratory Syndrome coronavirus disease><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome related corona virus 2><Shotguns><Siblings><Spain><Structure><Techniques><Technology><Testing><Therapeutic><Tissues><Transmission><United States><Vaccines><Variant><Variation><Viral Diseases><Virus><Virus Diseases><Virus Replication><Wuhan coronavirus><Zoonoses><Zoonotic><Zoonotic Infection><advanced age><angiotensin converting enzyme 2><angiotensin converting enzyme II><antibody based therapies><antibody treatment><antibody-based therapeutics><antibody-based treatment><base><case report><cell sorting><combination therapy><combined modality treatment><combined treatment><community spread><community transmission><community-level spread><community-level transmission><corona virus><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus emergence><coronavirus disease 2019><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 virus><coronavirus emergence><coronavirus infectious disease-19><defined contribution><developmental><disorder model><elders><emergent CoV><emergent corona virus><emergent coronavirus><emerging CoV><emerging corona virus><emerging coronavirus><experience><experiment><experimental research><experimental study><febrile><febris><geriatric><hCoV19><humAbs><human CoV><human corona virus><human coronavirus><human mAbs><human monoclonal antibodies><human monoclonals><immunogen><immunosuppressed patient><in vivo><interventional strategy><late life><later life><loss of function><mAbs><mortality><mouse model><multi-modal therapy><multi-modal treatment><murine model><nCoV><nCoV2><neutralizing mAb><neutralizing monoclonal antibodies><new CoV><new corona virus><new coronavirus><novel><novel CoV><novel corona virus><novel coronavirus><older adult><older person><pandemic><pandemic disease><prevent><preventing><pulmonary><receptor><senior citizen><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome-CoV><shot gun><transmission process><viral infection><viral multiplication><viral replication><virtual><virus infection><virus multiplication><virus-induced disease><zoonotic CoV><zoonotic coronavirus>